Changhua Ji1, Marc D Roy2, Jonathan Golas3, Allison Vitsky4, Sripad Ram5, Steven W Kumpf2, Matthew Martin2, Frank Barletta6, William A Meier7, Andrea T Hooper3, Puja Sapra3, Nasir K Khan8, Martin Finkelstein9, Magali Guffroy10, Bernard S Buetow5. 1. Immunotoxicology, DSRD, Pfizer, La Jolla, California. changhua.ji2@pfizer.com. 2. Investigative Toxicology, DSRD, Pfizer, Groton, Connecticut. 3. Oncology Targeted Therapeutics Discovery, Pearl River, New York. 4. Global Biomarkers, DSRD, Pfizer, La Jolla, California. 5. Global Pathology, DSRD, Pfizer, La Jolla, California. 6. Biomedicine Design, Pfizer, Pearl River, New York. 7. Covance Laboratories, Madison, Wisconsin. 8. DSRD Global Portfolio, Groton, Connecticut. 9. DSRD Global Portfolio, Pearl River, New York. 10. Global Pathology, DSRD, Pfizer, Pearl River, New York.
Authors: Tan Panpan; Du Yuchen; Shi Xianyong; Liu Meng; He Ruijuan; Dong Ranran; Zhang Pengyan; Li Mingxi; Xie Rongrong Journal: Cardiovasc Toxicol Date: 2022-07-25 Impact factor: 2.755
Authors: Francesca Castagnoli; Simon Doran; Jason Lunn; Anna Minchom; Mary O'Brien; Sanjay Popat; Christina Messiou; Dow-Mu Koh Journal: PLoS One Date: 2022-07-07 Impact factor: 3.752
Authors: Nicolas Palaskas; Juan Lopez-Mattei; Jean Bernard Durand; Cezar Iliescu; Anita Deswal Journal: J Am Heart Assoc Date: 2020-01-21 Impact factor: 5.501